PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.06
0.06 - 0.24
8.7K / 3.59M (Avg.)
-1.55 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1449386.90%
10Y CAGR of 1449386.90% while CRN.AX is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
No Data
No Data available this quarter, please select a different quarter.
288.78%
3Y CAGR of 288.78% while CRN.AX is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
128.62%
OCF/share CAGR of 128.62% while CRN.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
18.69%
OCF/share CAGR of 18.69% while CRN.AX is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
6365.04%
3Y OCF/share CAGR of 6365.04% while CRN.AX is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
58.96%
10Y net income/share CAGR of 58.96% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
66.19%
Net income/share CAGR of 66.19% while CRN.AX is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
-130.98%
Negative 3Y CAGR while CRN.AX is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-100.71%
Negative equity/share CAGR over 10 years while CRN.AX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-109.41%
Negative 5Y equity/share growth while CRN.AX is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-123.73%
Negative 3Y equity/share growth while CRN.AX is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.